Elixirgen Announces License Agreement with Sumitomo Dainippon Pharma
BALTIMORE, Nov. 19, 2015 — Elixirgen, LLC, a growing biotechnology company in Baltimore, announced today that it has entered an exclusive license agreement with Sumitomo Dainippon Pharma Co., Ltd., a major pharmaceutical company in Japan.
The agreement will focus on Elixirgen’s research regarding biologics targeting diseases associated with genome instability and chromosome abnormalities. Sumitomo Dainippon Pharma will gain exclusive rights for the further research (in part), development, and commercialization of the biologics in the region of Japan. Elixirgen will receive an upfront payment. In addition, Elixirgen is eligible to receive payments for development milestones, and royalties and milestones on the commercial sales of approved products in Japan. Outside of Japan, Elixirgen retains all rights.
“We are excited to work with one of the leading pharmaceutical companies in Japan for development and commercialization of our biologics in Japan. We believe this agreement will help accelerate our transition to clinical trials for our therapies,” said Naomi Ko, CEO of Elixirgen.
Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as the treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology. Additional information about Elixirgen is available at elixirgen.com.
About Sumitomo Dainippon Pharma:
Sumitomo Dainippon Pharma’s goal is to create innovative pharmaceutical products. Psychiatry & Neurology as well as Oncology represent our focus therapeutic areas containing significant unmet medical needs. It is channeling its R&D energies also into two new fields: diseases where no approved drugs exist as well as regenerative medicine/cell therapy. Additional information about Sumitomo Dainippon Pharma is available at www.ds-pharma.com.
CONTACT: Vanessa Harrington, 443-869-5420, email@example.com
Source: Elixirgen, LLC